lannett.investorroom.comLannett Company - Investor Relations

LinkedIn Contact Partnering Site Search Site Search About Leadership Board of Directors Facilities Partnership with Lannett News Contact Us Approach ES&G Environment Social Governance Products Patient Resources FAQ Medication Disposal Dependency and Support Investors Corporate Governance Senior Management Board of Directors Committee Charters News Releases Annual Reports Corporate Presentation SEC Filings Financial Reporting Stock Quote Interactive Chart Fundamentals Historical Stock Price Investment Calculator IR Snapshot IR Key Ratios Events and Webcasts Investor Alerts Get News Alerts by Email RSS Analyst Coverage Derivative Litigation Settlement Careers Culture Locations Current Openings Contact Partnering LinkedIn Investor RelationsInvestor Relations Lannett Company develops, manufactures, markets and distributes a broad spectrum of off-patent pharmaceutical products in a variety of dosage forms, including tablets, capsules, extended release, topicals, oral solutions and parenterals. The company is committed to product development and has built a deep pipeline that includes a substantial number of product applications pending at the FDA in addition to a large number of product candidates in various stages of development. Lannett has grown substantially since 2001 and intends to further grow its business organically, as well as by acquiring complementary products or companies and forming strategic relationships. The strategy for expanding its base generics business is to commercialize products in its pipeline, develop products with market barriers to entry, acquire complementary products and form strategic relationships. The company anticipates that the demand for its generic and branded medications will be fueled by, among other things, the aging Baby Boomer population. Lannett’s strong track record of regulatory compliance and manufacturing excellence, combined with strong management team, position the company well for the future. Recent News Investor Alerts May 2, 2023 LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION May 1, 2023 Lannett Company, Inc. Enters Into Restructuring Support Agreement Apr 20, 2023 NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS Upcoming Events No events to display Price Data NYSE LCI 1dy 1mo 6mo 1yr 5yr Authorized Distributors of Record Copyright © 2024 Lannett Site Map Privacy Policy Contact Us...